Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
Tanabe Pharma said on April 30 that it has won EU regulatory approval for Onerji (levodopa + carbidopa), a Parkinson’s disease therapy developed by its wholly owned Israeli subsidiary NeuroDerm. The green light was granted by the European Commission, dated…
To read the full story
Related Article
- FDA Again Rejects Mitsubishi Tanabe’s Parkinson’s Drug
October 24, 2025
- Mitsubishi Re-Files NeuroDerm’s Parkinson’s Drug in US
May 30, 2025
- Mitsubishi Tanabe’s Parkinson’s Drug Accepted for EMA Review
February 25, 2025
- Mitsubishi to Take Another Stab at Parkinson’s Drug Submission in US
November 5, 2024
- US FDA Snubs Mitsubishi Tanabe’s Parkinson’s Drug
June 12, 2024
- NeuroDerm’s Parkinson’s Med Hits Main Goal in PIII
January 11, 2023
BUSINESS
- BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
- Fuji Plans July Launch for Japan’s 1st Simponi, Ranmark Biosimilars
May 21, 2026
- Myelofibrosis Med Inrebic to Go on Sale June 1: Recordati Japan
May 21, 2026
- Fujifilm Opens New US Facility, Expands iPSC-Derived Cell Production
May 21, 2026
- High-Dose Uptravi Now Available: Nippon Shinyaku
May 21, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…